Search 

TomoWave is developing a new medical imaging modality of optoacoustic tomography, using ultrasound generated by laser light to provide doctors the capability to solve numerous problems in cancer diagnostics, surgery and minimally invasive therapy.

Gene Therapy company delivering Intrabodies with AAV delivery targeting misfolded proteins in neurodegenerative diseases. INT41 for Huntington’s Disease is our flagship product with successful results in cell based and animal models for Huntington's disease with additional indications. INT41 has Orphan Designation from the FDA.

Our platform selects Intrabodies that target novel intracellular mutations or stabilize refolding and can be applied to multiple therapeutic areas. 

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.  We have the only drug that treats low bladder capacity, which is an issue for 76% of nocturia sufferers.  Our clinical trial results were 5x better than the first FDA approved nocturia drug and 2.5x better than the other FDA approved nocturia drug, both of which carry a black warning about a dangerous blood disorder and have other side effects.  Of course these drugs treat polyuria rather than low bladder capacity, so they are not competitors for our drug.

Listed in China Growth Board, WolwoPharma is the biggest allergen drug manufacturer in China
and the largest allergen preparation supplier in Asia.

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

总部位于浙江的上市公司

创新性药物开发公司；已有多个仿制药和创新药上市；丰富的在研产品线；母公司已有两家上市公司，准备第3家公司上市；

总部加拿大温哥华的VC机构，负责把海外投资的项目引进国内商业化落地